- |||||||||| Eucrisa (crisaborole) / Pfizer, Daliresp (roflumilast) / AstraZeneca
Review, Journal: PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. (Pubmed Central) - Jun 25, 2024 Additionally, strategies to mitigate the adverse reactions of PDE4 inhibitors are discussed. This article emphasizes the need for further exploration of the therapeutic potential and clinical applications of PDE4 inhibitors in vascular diseases.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Review, Journal: Recent Advances in Phytochemical-Based Topical Applications for the Management of Eczema: A Review. (Pubmed Central) - May 25, 2024 This discussion delves into the efficacy of various nanocarriers, including liposomes, ethosomes, nanoemulsions, micelles, nanocrystals, solid-lipid nanoparticles, and polymeric nanoparticles. Consequently, the potential long-term side effects such as atrophy, eruptions, lymphoma, pain, and allergic reactions that are associated with current topical treatments, including emollients, topical corticosteroids, topical calcineurin inhibitors, and crisaborole, can potentially be mitigated through the use of phytochemical-based natural topical treatments.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Journal: Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged???2 Years with Mild to Moderate Atopic Dermatitis. (Pubmed Central) - May 15, 2024 P3 Consequently, the potential long-term side effects such as atrophy, eruptions, lymphoma, pain, and allergic reactions that are associated with current topical treatments, including emollients, topical corticosteroids, topical calcineurin inhibitors, and crisaborole, can potentially be mitigated through the use of phytochemical-based natural topical treatments. Crisaborole was effective and well tolerated in Chinese patients aged???2
- |||||||||| Eucrisa (crisaborole) / Pfizer
Allergic Contact Dermatitis in the Era of Glycemic Control Devices: Unveiling Sensitizing Allergens and Boosting Device Tolerance via Immunomodulation (Palma) - Apr 5, 2024 - Abstract #EAACI2024EAACI_808; The intervention phase involved preemptive application of topical treatments with either a phosphodiesterase-4 inhibitor (Crisaborole) or a calcineurin inhibitor (Tacrolimus) to the sites of the incident before re-exposure to the diabetes devices...Conclusion The findings highlight the restricted effectiveness of "original device adhesive patch testing" and underscore the importance of individualized allergen-focused assessments for customizing diabetes device selection. The positive response to the immunomodulatory treatment suggests the onset of a new therapeutic approach, considering the efficacy of device replacement as a solution, the high cost and limited availability of alternative devices for glycemic control.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Review, Journal: Advancing Treatment in Atopic Dermatitis: A Comprehensive Review of Clinical Efficacy, Safety, and Comparative Insights Into Corticosteroids, Calcineurin Inhibitors, and Phosphodiesterase-4 Inhibitors as Topical Therapies. (Pubmed Central) - Apr 2, 2024 The present investigation features the emergence of crisaborole, a phosphodiesterase four inhibitor...This study underscores the need for persistent investigation, teamwork, and innovations in managing AD. In this regard, AD requires a united approach between clinicians, researchers, affected individuals, and policymakers to refine patient-focused treatment and develop precise, economical strategies to address this chronic and frequently life-altering health condition.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Journal: A case of plasma cell vulvitis successfully treated with crisaborole. (Pubmed Central) - Apr 1, 2024 In this regard, AD requires a united approach between clinicians, researchers, affected individuals, and policymakers to refine patient-focused treatment and develop precise, economical strategies to address this chronic and frequently life-altering health condition. No abstract available
- |||||||||| Eucrisa (crisaborole) / Pfizer, Kerydin (tavaborole) / Pfizer
Journal: Design, Synthesis, and Antifungal Activity of 3-Substituted-2(5H)-Oxaboroles. (Pubmed Central) - Mar 20, 2024 These oxaboroles were nonhemolytic and nontoxic to rat myoblast cells (H9c2). Structure-activity relationship studies suggest that planarity is important for antimicrobial activity, possibly due to the effects of extended conjugation between the oxaborole and benzene rings.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Comparing real-world effectiveness and adverse effects of oral JAK inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study () - Feb 20, 2024 - Abstract #AAD2024AAD_2676; Patients aged 18 years or older with AD who initiated treatment with either oral JAKi (abrocitinib, baricitinib, or upadacitinib) or dupilumab were included...Those who initiated JAKi treatment presented with significantly less subsequent use of topical agents (including high-potency topical corticosteroids, calcineurin inhibitors, and crisaborole) (hazard ratio (HR), 0.86; 95% confidence interval (CI), 0.75-0.98), and atopic comorbidities (HR, 0.66; 95% CI, 0.54-0.80), including asthma (HR, 0.62; 95% CI, 0.48-0.79), allergic rhinitis (HR, 0.70; 95% CI, 0.54-0.91), and conjunctivitis (HR, 0.46; 95% CI, 0.29-0.73). These findings suggest that oral JAKi demonstrate better disease control than dupilumab and are well-tolerated for AD treatment.
- |||||||||| Jakafi (ruxolitinib) / Incyte, Eucrisa (crisaborole) / Pfizer, Opzelura (ruxolitinib cream) / Incyte
Chris, Jack, and You: Clinical pearls on the use of approved non-steroidal topical therapies, including crisaborole and ruxolitinib in AD (San Diego Convention Center, 111 W Harbor Dr., San Diego, CA 92101 | Room 30 AB) - Jan 29, 2024 - Abstract #AAD2024AAD_1704; Pimecrolimus can be considered as a first-line option for mild-to-moderate AD, particularly in children and sensitive skin areas. Sponsored by International Eczema Council
- |||||||||| Eucrisa (crisaborole) / Pfizer, Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
Clinical, Review, Journal: Phosphodiesterase-4 Inhibition in the Management of Psoriasis. (Pubmed Central) - Jan 23, 2024 This review summarizes evidence from randomized clinical trials regarding the efficacy and safety of PDE4 inhibitors in psoriasis treatment. By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis management.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Clinical guideline: Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. (Pubmed Central) - Dec 18, 2023 By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis management. These evidence-based recommendations address optimal use of (1) topical treatments (barrier moisturization devices, corticosteroids, calcineurin inhibitors, PDE4 inhibitors [crisaborole], topical JAK inhibitors, occlusive [wet wrap] therapy, adjunctive antimicrobials, application frequency, maintenance therapy), (2) dilute bleach baths, (3) dietary avoidance/elimination, (4) allergen immunotherapy, and (5) systemic treatments (biologics/monoclonal antibodies, small molecule immunosuppressants [cyclosporine, methotrexate, azathioprine, mycophenolate, JAK inhibitors], and systemic corticosteroids) and UV phototherapy (light therapy).
- |||||||||| Eucrisa (crisaborole) / Pfizer
PK/PD data, Preclinical, Journal: Confocal Raman Spectroscopic Characterization of Dermatopharmacokinetics Ex Vivo. (Pubmed Central) - Oct 6, 2023 Metrics related to local bioavailability (and potentially bioequivalence) included areas under the normalized C?N signal versus depth profiles and elimination rate constants deduced post-removal of the formulations. Finally, Raman measurements were made with an approved dermatological drug, crisaborole, for which delivery from a fully saturated formulation into the skin layers just below the SC was detectable.
- |||||||||| Eucrisa (crisaborole) / Pfizer, acoziborole (SCYX-7158) / SCYNEXIS
Review, Journal: Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design. (Pubmed Central) - Sep 18, 2023 Although boron phosphate-mimetic molecules - FDA-approved Crisaborole and phase II/III clinical candidate Acoziborole are products of the boron-phosphorus bioisosteric elemental exchange strategy, this technique is still in its infancy. The review aims to promote the use of this strategy in future medicinal chemistry projects.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
A Case of Erythema Multiforme Following Dupilumab Administration in a Pediatric Atopic Dermatitis Patient (Monitor 02) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_571; Dupilumab is a relatively new treatment option for eczema, with approval in young children coming in June 2022. While erythema multiforme is listed on the package insert as a possible adverse effect, it is very uncommon, illustrating the importance of continued vigilant observation, especially with new medications.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Preclinical, Journal: Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis. (Pubmed Central) - Aug 26, 2023 Calcium imaging of mouse dorsal root ganglion neurones revealed that pretreatment with S100A8/A9 significantly increased calcium responses to histamine and capsaicin, and the proportion of chloroquine-sensitive neurones. These findings suggest that the PDE4 inhibitor reduces itch and pain, in part by inhibiting infiltration of S100A8/A9-containing neutrophils in a mouse model of MC903-induced atopic dermatitis.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Trial completion date, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Aug 1, 2023 P1, N=28, Active, not recruiting, We can thereby conclude that nanoemulgel formulation can be a successful drug delivery strategy for enhancing the therapeutic effect of CB. Trial completion date: Jul 2023 --> Dec 2023
- |||||||||| Eucrisa (crisaborole) / Pfizer
Enrollment change, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Jul 3, 2023 P1, N=28, Active, not recruiting, No abstract available N=40 --> 28
- |||||||||| What () - Jul 3, 2023 - Abstract #WCD2023WCD_5896;
There are multiple new treatments on the horizon for AA. Our review focuses on recent clinical trials for this condition and highlights what is to come as far as new and emerging treatments
- |||||||||| clobetasol propionate topical / Generic mfg.
Comparison of Effectiveness of Topical Treatments for Atopic Dermatitis () - Jun 19, 2023 - Abstract #RAD2023RAD_109; There is a lack of head-to-head trials for topical treatments for AD. Due to the tremendous burden of AD on patients' physical and mental health, there is a need for additional therapies.
- |||||||||| lirentelimab (AK002) / Allakos
Phase 2 Trial in Progress () - Jun 19, 2023 - Abstract #RAD2023RAD_75; P2 Due to the tremendous burden of AD on patients' physical and mental health, there is a need for additional therapies. The results of these studies provide a strong rationale for conducting this phase 2 proof-of-concept, randomized, double-blind, placebo-controlled study of lirentelimab SC in adults with moderate
- |||||||||| Moizerto (difamilast) / Otsuka, Medimetriks
Journal: Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for the Topical Treatment of Atopic Dermatitis. (Pubmed Central) - Jun 19, 2023 Significance Statement This is the first report on the nonclinical pharmacological profile of difamilast ointment, a novel topical PDE4 inhibitor that demonstrated utility in clinical trials in patients with atopic dermatitis. Difamilast, which has high PDE4 selectivity (especially for the PDE4B subtype), ameliorated chronic allergic contact dermatitis in mice after topical application, with a pharmacokinetic profile in animals that suggests few systemic side effects; thus, difamilast is a promising new therapeutic treatment for atopic dermatitis.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Enrollment closed: Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) - Jun 9, 2023 P4, N=60, Active, not recruiting, Difamilast, which has high PDE4 selectivity (especially for the PDE4B subtype), ameliorated chronic allergic contact dermatitis in mice after topical application, with a pharmacokinetic profile in animals that suggests few systemic side effects; thus, difamilast is a promising new therapeutic treatment for atopic dermatitis. Recruiting --> Active, not recruiting
|